Zydus Cadila has been granted permission by India’s drug regulator to conduct a Phase III trial on the two dose regimen of its needle-free Covid-19 vaccine, ZyCoV-D. The Subject Expert Committee (SEC), which advises the drug regulator, granted the company permission to conduct Phase III trials on its vaccine at a meeting last month.
“After careful consideration, the committee recommended that permission be granted to conduct the Phase III clinical trial, subject to the condition that the volume of blood to be withdrawn in the paediatric cohort be in accordance with the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants issued by the ICMR,” according to the meeting minutes.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…